THURSDAY, Oct. 28 (HealthDay News) -- A new noninvasive test to
detect pre-cancerous polyps and colon tumors appears to be more
accurate than current noninvasive tests such as the fecal occult
blood test, Mayo clinic researchers say.
The search for a highly accurate, noninvasive alternative to
invasive screens such as colonoscopy or sigmoidoscopy is a "Holy
Grail" of colon cancer research.
In a preliminary trial, the new test was able to identify 64
percent of pre-cancerous polyps and 85 percent of full-blown
cancers, the researchers reported.
Dr. Floriano Marchetti, an assistant professor of clinical
surgery in the division of colon and rectal surgery at University
of Miami Sylvester Comprehensive Cancer Center, said the new test
could be an important adjunct to colon cancer screening
if it proves itself in further study.
"Obviously, these findings need to be replicated on a larger scale," he said. "Hopefully, this is a good start for a more reliable test."
Dr. Durado Brooks, director of colorectal cancer at the American
Cancer Society, agreed. "These findings are interesting," he said.
"They will be more interesting if we ever get this kind of data in
a screening population."
The study's lead researcher remained optimistic.
"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion," noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.
"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening," he said. "And screening not only in a way that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream."
Ahlquist was scheduled to present the findings of the study
Thursday in Philadelphia at a meeting on colorectal cancer
sponsored by the American Association for Cancer Research.
The new technology, called the Cologuard sDNA test, works by
identifying specific altered DNA in cells shed by pre-cancerous or
cancerous polyps into the patient's stool.
If a DNA abnormality is found, a colonoscopy would still be
needed to confirm the results, just as happens now after a positive
fecal occult blood test (FOBT) result.
To see whether the test was effective, Ahlquist's team tried it
out on more than 1,100 frozen stool samples from patients with and
without colorectal cancer.
The test was able to detect 85.3 percent of colorectal cancers
and 63.8 percent of polyps bigger than 1 centimeter. Polyps this
size are considered pre-cancers and most likely to progress to
cancer, Ahlquist said.
The sensitivity of the test is much better than what has been
seen in other stool screening tests, the ACS' Brooks added. "But,
showing that in a small group of samples is very different from
demonstrating that in a population where only a small number of
individuals are going to have polyps of that size. Then we will
know if this is a big step forward," he said.
According to Ahlquist, Cologuard is the first noninvasive test
to detect pre-cancerous polyps, he added.
In addition, the test is the only one that is able to identify
cancer in all locations throughout the colon, something which other
tests either can't or don't do well, Ahlquist said.
One more advantage: patients do not need to do any special
preparation before taking the test, something that other tests
require, he added.
Ahlquist noted that the test still needs to be refined. "We
learned there are still some bugs and we can make the test even
better," he said.
Cologuard is not yet available for sale. Clinical trials
comparing the test with colonoscopy are slated to start next year.
Ahlquist hopes that the test will be approved and available within
Ahlquist noted that the cost of the test has not yet been
established. It is expected to cost more than a fecal occult blood
test, but far less than a colonoscopy. A fecal occult blood test
can cost as little as $23 while a colonoscopy can total $700.
Another benefit is that it would probably need to be done once
every three years, while the fecal occult blood test is usually
done yearly. Savings over time on a more accurate test done fewer
times could justify the higher cost of the Cologuard test, Ahlquist
In two other presentations at the meeting, researchers have
linked key gene variants to the risk for colon cancer and also to
the prognosis of the disease.
In one study, researchers found that people who have long
telomeres, the small strips of DNA that cover the ends of
chromosomes, have a 30 percent increased risk of developing colon
"Even for people their age, their telomeres were longer than you'd expect for healthy people," lead researcher Dr. Lisa A. Boardman, an associate professor of medicine at the Mayo Clinic, said in a statement. "This suggests that there may be two different mechanisms that affect telomere length and that set up susceptibility to cancer," she said.
In the other study, a research team led by Kim M. Smits, a
molecular biologist and epidemiologist in the GROW-School for
Oncology and Developmental Biology at Maastricht University Medical
Center in the Netherlands, uncovered a surprise when it came to a
gene variant on the KRAS gene called the G variant. This variant,
long linked to poorer outcomes in advanced colorectal cancer,
actually predicted a better prognosis in early-stage colon
"You would intuitively think that the G variant would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case," Smits said in a statement.
Experts point out that studies presented at scientific meetings
do not have to pass the rigorous peer review of studies published
in reputable journals.
For more information on colon cancer, visit the
American Cancer Society.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.